T
TransThera Biosciences
Research and development of innovative drugs in oncology, cardiovascular, and inflammatory diseases
About TransThera Biosciences
A clinical-stage biopharmaceutical company specializing in the development of small-molecule drugs to address unmet medical needs. The company's research and development efforts are concentrated on therapeutics for oncology, cardiovascular, and inflammatory diseases.
TransThera Biosciences operates in the biotechnology sector, focusing on advancing its pipeline of drug candidates through clinical trials. The company has received Investigational New Drug (IND) approval from the FDA for its drug candidate TT-00920, intended for the treatment of chronic heart failure. This milestone allows the company to initiate Phase 1 clinical trials to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug.
The company's business model involves strategic research and development collaborations, such as the one with Teijin Pharma, to advance its therapeutic programs. By focusing on areas with significant unmet medical needs, TransThera Biosciences aims to develop and commercialize novel treatments for a global market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2025
- Outcome tier
- Unicorn$1–10B valuation tier
News
Open roles
TransThera Biosciences in the Nanjing City ecosystem
The TransThera Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
- GCGP Capital
Series B and later19 investors entered at this stage
- OFOcean Pine Healthcare Fund
SDIC Venture Capital- SMShenzhen Cornerstone Asset Management
- EVEnnovation Ventures
- GCGrand Yangtze Capital
- CCChina Merchants Capital
CITIC PE
China Structural Reform Fund
China Renaissance- GCGP Healthcare Capital
Sixty Degree Capital- RHRuihua Holdings
Trinity Innovation Fund- DCDunhang Capital
- GQGuolian Financial Investment Qiyuan
- NANanjing Jiangbei State-owned Assets
- RCRuitong Venture Capital
- BIBOCG Investment
- GCGuoxin Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
81 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about TransThera Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TransThera Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

